NLS Pharmaceutics Warrant
NLSPW
NLSPW was delisted on the 30th of October, 2025.
5 hedge funds and large institutions have $886K invested in NLS Pharmaceutics Warrant in 2021 Q1 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$455K |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$182K |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$177K |
| 4 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$31.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2.84K |
Top Sellers
NLSPW Hedge Fund Activity: Q1 2021 in Review
5 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in NLS Pharmaceutics Warrant (NLSPW) for Q1 2021, worth a combined $886K.
Buyers outnumbered sellers: 5 funds opened new NLSPW positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $455K.
- 5 institutional investors held NLS Pharmaceutics Warrant (NLSPW) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $886K of NLS Pharmaceutics Warrant stock for Q1 2021.
- 5 funds opened new NLS Pharmaceutics Warrant positions in Q1 2021 and 0 closed out, a net change of +5 holders.
- The largest NLS Pharmaceutics Warrant buyer in Q1 2021 was Armistice Capital, an estimated $455K added.
Based on aggregated 13F filings for Q1 2021.